僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Nivolumab （anti-PD-1） is a genetically engineered, fully human immunoglobulin （Ig） G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 （PD-1,PCD-1） with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.